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Role of aldosterone in the control of sodium excretion in patients
with advanced chronic renal failure. The factors that regulate so-
dium and potassium excretion in patients with chronic renal fail-
ure have not been fully clarified. The role of aldosterone in the
control of sodium and potassium excretion was therefore exam-
ined in eight normokalemic patients with chronic renal failure
(mean creatinine clearance. 14.3 mI/mm). With a normal sodium
intake (120 to 151 mEq/24 hr), plasma aldosterone levels were
above normal in five of the eight patients and in five of six pa-
tients with a creatinine clearance of less than 15 mI/mm. Aldoste-
rone levels were further increased in all eight patients by as-
sumption of an upright posture (from a mean of 523 to 1,454 pgl
ml, P < 0.01). When seven of the patients were placed on a low
sodium diet (10 to 20 mEq/24 hr), mean plasma aldosterone lev-
els increased from 587 to 2.393 pg/mI; (P < 0.02). The low sodium
diet was also associated with a fall in mean body of 2.1 kg and a
decrease in plasma sodium concentration from 140 to 131 mEq/
liter (P < 0.005) in all patients. To further define the physiologic
role of the high aldosterone levels, we administered the aldoste-
rone antagonist, spironolactone (300 mg124 hr), to the patients
while they were on a normal sodium diet. The administration of
spironolactone was associated with a significant natriuresis, as
mean sodium excretion increased from 142 to 173 mEqI24 hr (P
<0.02) and mean body wt decreased by 1.4 kg (P< 0.02). With
the administration of spironolactone, the mean potassium excre-
tion decreased from 47 to 41 mEq/24 hr (P <0.05) as plasma po-
tassium rose from 4.6 to 5.4 mEq/liter (P < 0.01). We conclude
that (1) many normokalemic patients with advanced renal failure
(creatinine clearance < IS mI/mm) are in a state of hyper-
aldosteronism. (2) nevertheless, the secretion of aldosterone in
these patients can be stimulated further by posture and volume
depletion, and 3) aldosterone plays a physiologic role not only in
the maintenance of serum potassium concentration but also as an
antinatriuretic force in advanced chronic renal failure.
Role de l'aldostérone dans le contrOle de l'excrétion du sodium
au cours de l'insufllsance rénale avancée. Les facteurs qui reglent
l'excrétion du sodium et du potassium chez les malades atteints
d'insuffisance rénale ne sont pas complètement connus. Le role
de l'aldostérone dans le contrôle de l'excrétion du sodium et du
potassium a donc été étudié chez huit malades normo-kalié-
miques atteints d'insuffisance rénale chronique (clearance
moyenne de Ia créatinine: 14.3 mI/mm). Quand l'apport de so-
dium est normal (120—151 mEq/24 hr), les concentrations plasma-
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tiques d'aldostérone sont supeneures a Ia normale chez cinq
des huit malades et chez cinq des six dont Ia clearance de Ia
créatinine est inférieure a 15 mI/mm. Les concentrations d'al-
dostérone sont encore augmentées chez tous les huit sujets
par le passage a Ia position debout (523 a 1454 pg/mI; P < 0,01).
Quand sept de ces malades ont été mis a un régime pauvre en
sodium (10—20 mEq/24 hr). Ia concentration moyenne de
l'aldostérone a augmenté de 587 a 2393 pg/mI (P < 0.02). Le ré-
gime pauvre en sodium a été associé a une diminution du poids
corporel de 2,1 kg en moyenne et d'une diminution de Ia concen-
tration plasmatique du sodium de l40à 131 mEq/litre(P <0,005)
chez tous les malades. Afin de mieux définir le role physio-
logique des concentrations élevées d'aldostérone Ia spironolac-
tone a été administrée aux malades. alors que leur régime était
normal en sodium. Cette administration a été associée a une nat-
riurèse significative. l'excrétion moyenne de sodium est passée
de 142 a 173 mEq/24 hr (P < 0.02) et le poids corporel moyen a
diminué de 1,4 kg (P < 0.02). Sous l'effet de Ia spironolactone
l'excrétion moyenne de potassium a diminué de 47 a 41 mEq/24h
(P < 0.05) pendant que Ia kaliémie passait de 4,6 a 5,4 mEq/litre
(P <0,01). Nous concluons que (I) beaucoup de malades atternts
d'insuffisance rénale avancée (clearance de Ia créatinine < 15
mi/mm) sont en état d'hyperaldostéronisme. (2) cependant Ia
secretion d'aldostérone chez ces malades peut encore etre stim-
ulée par Ia posture et Ia diminution du volume extracellulaire. et
(3) l'aldostérone joue un rOle physiologique non seulement dans
Ic maintien de Ia kaliémie mais aussi comme facteur anti-
natriurétique au cours de l'insuffisance rénale avancée.
The factors that control sodium excretion in pa-
tients with advanced renal failure have been the
subject of intense investigation [1—41, and the role of
aldosterone in this control mechanism has been a
matter of controversy. For example, it is unclear
whether or not advanced renal failure is associated
with a state of hyperaldosteronism. Such a state of
hyperaldosteronism has been proposed since some
studies have reported an increase in aldosterone se-
cretory rates in patients with chronic renal failure
who were on a normal sodium intake [5—7]. On the
other hand, no such increase in aldosterone produc-
tion was found with in vitro adrenal slices in the ure-
mic rat [8]. Also, urinary aldosterone excretions in
patients with chronic renal failure have been report-
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ed to be normal [9, 101. Measurements of both al-
dosterone excretion and secretion, however, suffer
shortcomings in patients with chronic renal failure,
which makes their interpretation difficult. Specifi-
cally, because of delayed excretion of the isotope-
labeled aldosterone, determinations of aldosterone
secretory rates are wrought with methodologic
problems in chronic renal failure [51, and the uri-
nary excretion rates of the hormone may be a poor
reflection of its circulating plasma levels in patients
with poor renal function.
In contrast to the very extensive studies available
on plasma aldosterone and its regulation in the
anephric state [11—171, as well as in patients on
chronic hemodialysis [11, 18], very scant data are
available in nondialyzed patients with advanced
renal insufficiency [11, 19]. Furthermore, the physi-
ologic role that the hormone may play in the setting
of severe renal failure has not been defined. Al-
though the adaptive increase in sodium excretion
per nephron that accompanies the uremic state ap-
pears not to be dependent on decreases in mineral-
ocorticoid hormone [20], aldosterone could still be
exerting an important antinatriuretic influence in
patients with advanced renal failure. The present
study, therefore, was performed to determine the
circulating levels of aldosterone and its response to
physiologic stimuli in normokalemic patients with
advanced renal insufficiency and to ascertain the
role that the hormone plays in the control of sodium
excretion in these patients.
Methods
Studies were performed on eight patients (five
males and three females) with advanced renal in-
sufficiency of various etiologies (Table 1). These pa-
tients had no clinical evidence of uremia, hyper-
tension, edema, congestive heart failure, volume
contraction, acute urinary tract obstruction, or in-
fection. None were on diuretics, antihypertensive
agents, sodium restriction, or sodium supplementa-
tion prior to the study. The protocol used was ap-
proved by the Human Experimentation Committee,
and each patient consented to participate in the
study. Studies were performed in the Clinical Re-
search Center of Colorado General Hospital. Pa-
tients were studied in the following conditions.
Normal sodium intake. Each patient was placed
on a constant diet which was consumed throughout
the study period. With the exception of one pa-
tient's diet (patient no. 4), which had 120 mEq of
sodium, all other diets contained between 145 and
141 mEq of sodium per 24 hr. Dietary potassium
content likewise was kept constant in each patient
and ranged from 45 to 83 mEq/24 hr. Protein intake
was limited to 50—60 g/day. Water intake was al-
lowed ad jib. Plasma aldosterone levels and plasma
renin activities were determined at 8:00 and 10:00
A.M. on 2 consecutive days, after 5 or 6 days of the
diet. The 8:00 A.M. measurements were performed
after the patients had been in the supine position for
8 hours, and the 10:00 A.M. measurements were
performed after the patients had been in normal up-
Table 1. Effect of low sodium intake on creatinine clearance, serum sodium, potassium, and body weight on patients with advanced
chronic renal failure
Creatinine
clearance Serum sodium Potassium
Weight, kg mI/mm mEq/liter mEq/liter
Normal Low Normal Low Normal Low Normal Low
Patient sodium sodium sodium sodium sodium sodium sodium sodium
no. Age Sex Diagnoses diet diet intake intake intake intake intake intake
1 60 M Glomerulonephritis 83 81 8 7 143 131 4.6 5.9
2 24 F Polycystic kidney dis. 59 58 9 7.5 137 124 4.0 4.9
3 37 F Interstitial disease 44 43 12 8 140 133 5.4 5.1
4 47 M Reflux nephritis 79 76 10 10 138 132 4.1 4.9
5 24 F Chronicglomerulonephritis 96 90 9 7 143 127 4.2 5.1
6 22 M Hereditary nephritis 72 72 11 9 143 135 4.6 3.8
7 54 M Glomerulonephritis 70 68 33 34 138 136 4.7 5.0
Mean 71.8 69.7 13.1 11.8 140.0 131.0 4.50 4.95
SEM 6.0 6.0 3.3 3.7 1.0 1.6 0.18 0.23
P value <0.025 NS <0.005 NS
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right activity for 2 hours. A regimen of spironolac-
tone was then started: Aldactone®. 75 mg orally,
every 6 hours for 3 to 5 days (mean, 4.6 days).
Low sodium intake. Seven of the eight patients
also received a diet containing 10 to 20 mEq of so-
dium per 24 hours. The potassium and protein con-
tent of the diet was unchanged from that which the
patients consumed when on the normal sodium diet.
After the patients had been on this diet for 5 to 7
days, we measured the plasma aldosterone concen-
trations and plasma renin activities for two con-
secutive days. again at 8:00 and 10:00A.M., with the
patients in the supine and upright positions, respec-
tively.
Plasma aldosterone levels were determined by ra-
dioimmunoassay as previously described [21, 221.
Since the antibody employed in this assay is highly
specific for aldosterone [211, it is most unlikely that
a metabolite that may accumulate in renal failure is
the cause for a falsely elevated measurement. The
normal levels of plasma aldosterone with the same
assay have been previously reported [221. With a
normal sodium intake (mean urinary sodium of 113
mEq/24 hr), plasma aldosterone levels ranged from
32 to 264 pg/mi (mean, 124 13; N = 22) for the
supine position and increased to a range of from 149
to 480 pg/mI (mean, 344 24; N = 16) after 2 hours
of upright posture. With the institution of a sodium
restricted diet (urinary sodium below 30 mEq/24
hr), the plasma aldosterone value in 14 normal vol-
unteers ranged from 268 to 520 pglml (mean, 387
39) for the supine position and increased further to a
range of from 416 to 1,706 pg/mI (mean, 912 108)
for the upright position. Plasma renin activity was
measured by radioimmunoassay of generated angio-
tensin. In our laboratory, the normal plasma renin
activity of subjects on a normal sodium intake (uri-
nary sodium over 110 mEq/liter) is 1.58 0.24 ng of
angiotensin I (A!) per ml per hr for the supine posi-
tion and 4.38 0.93 ng of AI/mllhr for the upright
position. With a sodium-restricted diet (urinary so-
dium below 30 mEq/24 hr), mean plasma renin ac-
tivity was 7.0 1.3 ng of AI/mLlhr for the supine
position and 15.8 1.85 for the upright position
[231. Measurements of blood pressure, weight, and
fluid balances were recorded daily. Sodium, potas-
sium (flame photometer), calcium (atomic absorp-
tion), and creatinine (autoanalyzer) measurements
were made in the collected urine samples. Blood
tests other than aldosterone and plasma renin activ-
ity included alternate day measurements of urea ni-
trogen, creatinine, and plasma electrolytes. The
plasma potassium was measured daily while the pa-
tients received spironolactone; the drug was discon-
tinued if the plasma potassium exceeded 6.5 mEq/
liter.
Statistical analysis was performed with paired
Student's t test and, where applicable, with non-
parametric analysis (Wilcoxon rank test). A P value
of < 0.05 was considered significant.
Results
Effect of changes in posture and sodium intake
on serum aldosterone levels in patients with ad-
vanced renal failure (Table 1, Fig. 1). The ability of
patients with advanced renal insufficiency to in-
crease their circulating plasma levels of aldosterone
in response to various stimuli was studied with each
patient serving as his own control. The hormone
was measured for the supine and upright positions
on 2 consecutive days when the patients were on a
normal sodium intake and on 2 consecutive days
when on a reduced sodium diet. The mean of the
two determinations is depicted in Figure 1.
Five of the eight patients had plasma aldosterone
levels that were clearly above the range of normal
control subjects on a normal sodium intake in both
the upright and supine positions. The levels of the
hormone rose in each patient in the change from the
supine to the upright posture from a mean (± SEM)
of 523 321 to 1,454 667 pglml (P <0.01). Like-
wise, with the institution of a low sodium diet for 5
to 7 days, at which time mean urinary sodium ex-
cretion fell from 146 to a mean of 37 mEq/24 hr,
each of seven patients had a further increase in
plasma aldosterone level both for the supine (587
364 to 2,393 985 pg/ml; P < 0.02) and upright
(1,249 748 to 4,299 1,725 pg/mI; P <0.02) pos-
tures.
The effects of this low sodium intake on the vari-
ous factors that could affect the secretion of the hor-
mone are shown in Table 1. The mean serum creati-
nines were not statistically different, but renal func-
tion did decrease in five of the patients. Likewise,
the mean serum potassium concentrations were not
statistically different but did rise in five of the sub-
jects. Mean (± SEM) plasma renin activity was in-
creased from 7.81 2.9 to 20.6 6.3 ng of AI/mllhr
by posture and to 19.1 8.8 ng of AI/mllhr by de-
crease in sodium intake. Because of the interpatient
variability, however, neither of these increases at-
tained statistical significance. All patients lost
weight, with a mean loss of 2.1 kg (P <0.025), and
they all sustained a significant decrease in serum so-
dium concentration as the mean decreased from 140
to 131 mEq/liter (P < 0.005).
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Effect of spironolactone on sodium and potas-
sium metabolism in patients with advanced renal
insufficiency (Table 2, Fig. 2). The mineralocor-
ticoid antagonist, spironolactone, was administered
in a dosage of 75 mg, per os, every 6 hours to
evaluate the physiologic role of aldosterone in the
control of sodium excretion in patients with ad-
vanced renal disease. The aldosterone antagonist
was administered to eight patients after they were in
sodium balance on a constant normal sodium in-
take. Sodium balance was considered achieved
when on three consecutive 24-hr collections urinary
sodium excretions did not deviate by more than 10
mEq from the sodium content of the diet. The spi-
ronolactone antagonist was administered to one pa-
tient on a low sodium diet who developed nausea
and vomiting in association with a negative sodium
balance and hyperkalemia. Because of ethical con-
siderations, therefore, we decided not to combine
sodium restriction and aldosterone antagonism in
these patients with advanced renal failure. The ef-
fect of spironolactone on the excretion of sodium is
depicted in Figure 2. The aldosterone antagonist
caused an increase in sodium excretion in seven of
the eight patients studied, as mean (± SEM) sodium
excretion rose from 142 4.4 to 173 8.8 mEq/24
Table 2. Effect of spironolactone (SP) on creatinine clearance, serum sodium, potassium, bicarbonate, and calcium excretion in patients
with advanced chronic renal failure
Creatinine Calcium
Weight clearance Serum sodium Potassium Bicarbonate excretion
Patient kg
mi/mm mEq/liter mEq/iiter mEqiliter mg/24 hr
no. Days on SP Control SP Control SP Control SP Control SP Control SP Control SP
1 5 83 83 8 9 143 140 4.6 4.6 18 19 12 13.5
2 5 59 58 9 7 137 134 4.0 6.0 26 22 71 77
3 4 44 43 12 9 140 141 5.4 6.5 16 16 38 42
4 3 79 78 10 10 138 137 4.1 4.9 14 15 21 26
5 5 96 93 9 9 143 138 4.2 5.1 16 18 30 28
6 5 72 72 11 11 143 139 4.6 4.9 14 15 98 90
7 5 70 68 33 33 138 132 4.7 5.5 22 19 12 II
8 5 65 62 25 19 140 140 5.0 5.4 19 19 53 52
Mean 71.0 69.6 14.6 13.4 140.2 137.6 4.60 5.40 18.1 17.8 41.9 42.4
SEM 6.0 5.5 3.2 3.1 0.8 1.1 0.17 0.22 1.4 0.8 10.7 10.2
P value 0.02 NS 0.02 0.01 NS NS
Fig. 1. Plasma aldosterone levels in the supine (left panel) and upright posture (right
panel) in normokalemic patients with advanced renal insufficiency on normal and low
sodium diet. Hatched areas represent the normal ranges in controls with intact renal and
adrenal function. Sodium restriction consistently increased aldosterone levels in every
patient.
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hr (P < 0.02). The eighth patient, who did not re-
spond to spironolactone, was the one with the low-
est serum aldosterone levels (patient no. 1). The
mean cumulative negative sodium balance over the
period of spironolactone administration was a total
of 116 mEq. As shown in Table 2, this negative so-
dium balance was associated with a significant de-
crease in body weight (P <0.02). In all but one pa-
tient whose urinary sodium excretion increased,
this occurred in the absence of an increase in the
filtered load of sodium. The mean creatinine clear-
ance was not significantly changed in the group as a
whole but was decreased in three patients. The
mean serum sodium concentration decreased from
140 to 137 mEq/liter (P < 0.02). Furthermore, this
observed natriuresis was not a consequence of an
increase in calcium excretion, like that which oc-
curs in normal subjects receiving spironolactone
[24]. The well-recognized low calcium excretion of
advanced renal failure was present in our patients,
but it remained essentially unaltered by the aldoste-
rone antagonist.
In addition to its effect on sodium excretion, spi-
ronolactone also decreased potassium excretion, as
the mean (± SEM) excretion of the cation fell from
46.9 1.0 to 41.5 2.5 mEq/24 hr (P <0.05). At
the same time, serum potassium concentration rose
from 4.6 to 5.4 mEq/liter (P < 0.01). This increase
in serum potassium concentration was not associat-
ed with a change in serum bicarbonate concentra-
tion.
Discussion
The elevated plasma aldosterone levels for a nor-
mal sodium intake in five of our patients suggest
that many patients with far advanced chronic renal
failure may be in a state of hyperaldosteronism.
These findings may appear to be in conflict with
studies in which urinary aldosterone excretion was
found to be normal in patients with chronic renal
failure [9, 10]. As with other substances, however,
such as creatinine, urinary excretion rates in chron-
ic renal failure may be normal despite high blood
levels of the substance. Williams et al [11] also has
reported high serum aldosterone levels in patients
with chronic renal failure who are not on dialysis,
but the state of sodium balance in these patients
was not documented. Likewise, in the study of
Weidman et al [19], the aldosterone levels in four
normokalemic patients with chronic renal failure
were slightly but significantly higher than were
those of controls. The aldosterone levels in most of
our patients, however, were even higher than those
found in these previous studies [11, 19]. This quan-
titative difference may well relate to the more se-
vere degree of renal impairment of the subjects in
our study. In this regard, two of the three patients in
the present study who had normal plasma levels of
Normal Normal sodium diet
sodium diet + spironolactone
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Fig. 2. Effect of spironolactone on urinary sodium excretion in patients with advanced renal
failure on normal sodium intake. The increase in sodium excretion was significant at the
P < 0.02 level, and the decrease in potassium excretion was significant at the P < 0.05
level.
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aldosterone had the highest creatinine clearances
(25 and 33 mllmin). Hyperaldosteronism was pres-
ent in five of six patients with a creatinine clearance
lower than 15 mI/mm. The high levels of aldoste-
rone in the present study contrast with the normal
aldosterone levels found in most patients on chronic
hemodialysis, both by others [11, 18] and, more re-
cently, in our own laboratory [25]. The reason for
this difference is not clear, but there are several
possible explanations. First, the stimulation of a!-
dosterone normally provided by the renin-angioten-
sin system may be attenuated in patients on dialysis
with end-stage kidney diseases [18]. If such patients
have been nephrectomized in association with renal
transplantation, this is certainly the case. Further-
more, it appears that most patients on chronic dial-
ysis sustain chronic potassium losses that frequent-
ly culminate in potassium depletion [26, 27]. This
decrease in total body potassium may involve the
adrenal gland and thereby be at least partially re-
sponsible for the suppression of aldosterone secre-
tion. Finally, hemodialysis patients are subjected to
repeated administration of heparin, which in doses
of approximately 300 mg/day may interfere with al-
dosterone excretion [28].
On the basis of the present results, it seems likely
that the increase in aldosterone levels found in our
patients with advanced renal failure is of homeo-
static importance in protecting such patients against
potentially fatal hyperkalemia. This possibility is
supported by the increase in serum potassium con-
centration which occurred when our patients re-
ceived spironolactone. Also, the hyperkalemia re-
ported in patients with mild decreases in renal func-
tion who are aldosterone deficient suggests that
mineralocorticoid hormone activity is important in
potassium homeostasis over a wide range of renal
function [29]. Advanced chronic renal failure ap-
pears to be associated with generous fecal potas-
sium losses [30, 31]. Whether aldosterone accounts
for some of these losses remains to be determined,
but earlier studies do not appear to demonstrate
such an effect [9, 30].
The suggestion has been made that since aldoste-
rone may circulate in high concentrations in pa-
tients with advanced renal insufficiency, the adrenal
cortex may not respond normally to known stimuli
[3]. Our results, however, do not support this pro-
posal. In our patients, a change from the supine to
the upright posture, as well as a decrease in sodium
intake, was consistently associated with increased
plasma levels of the hormone (Fig. 1). The changes
noted with posture could have been due, at least in
part, to decreased degradation of aldosterone sec-
ondary to a diminution in hepatic blood flow [32]. In
normal man, however, studies show that sodium
deprivation does not change the metabolic clear-
ance of aldosterone [33]; thus, the resulting in-
creased levels of aldosterone are felt to reflect in-
creased hormone secretion.
In the present study, several stimuli may have
mediated the effect of a decrease in sodium intake
to increase plasma aldosterone concentration. With
sodium restriction, the plasma renin activity in-
creased in most patients during the low sodium in-
take period. Although a close correlation between
the rise in renin and aldosterone was not observed,
the patients with lowest renin activities also had the
lowest levels of aldosterone. An increase in plasma
potassium concentration also may have contributed
to the rise in aldosterone level with sodium restric-
tion, since potassium concentration rose in five of
the patients. Likewise, the observed decrease in
serum sodium concentration could have contrib-
uted to the noted increase in aldosterone level [16].
Finally, the extracellular volume contraction during
sodium restriction could have stimulated aldoste-
rone secretion through an as yet undefined path-
way. Inasmuch as all these factors changed with the
institution of the low sodium diet, their relative
roles in stimulating aldosterone secretion cannot be
clearly dissected. A recent study in patients on dial-
ysis underlined, however, the importance of potas-
sium in the secretion of aldosterone, as levels of the
hormone decreased with decreasing serum potas-
sium concentrations despite volume and renin stim-
uli that favored the secretion of the hormone [25].
As with potassium homeostasis, in the present
study the physiological importance of aldosterone
in advanced renal failure on sodium balance was ex-
amined by administering the aldosterone antago-
nist, spironolactone. Seven of the eight subjects had
a natriuresis, as mean urinary sodium excretion in-
creased from 142 to 173 mEq/24 hr (P <0.02) during
the 3 to 5 days of spironolactone administration.
Again, the one patient who failed to show a natri-
uresis was the patient (patient no. 1) whose serum
aldosterone levels were the lowest. This increase in
urinary sodium excretion occurred despite a de-
crease in the filtered load of sodium in all but one of
the patients. The natriuresis also was not associated
with an increase in calcium excretion, which has
been reported during spironolactone administration
to normal subjects [24]. As expected, therefore, the
changes in sodium excretion seemed to reflect the
effect of spironolactone to inhibit the action of a!-
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dosterone on the renal tubule. The effect of spirono-
lactone to enhance sodium excretion in our patients
on a normal sodium intake makes it likely that an
even more marked effect would be observed when
such patients are on low sodium intake and have
higher plasma aldosterone levels. Because of ethi-
cal consideration, our patients with advanced renal
failure were not treated with spironolactone while
on a low sodium intake. A previous study, how-
ever, showed that spironolactone administration
causes a natriuresis in patients on a low sodium in-
take with less severe renal failure than that which
was present in the current group of patients [9]. It
seems likely, therefore, that the antinatriuretic ef-
fect of aldosterone is important in sodium homeo-
stasis in advanced chronic renal failure during both
normal and low sodium intakes.
In conclusion, the present study suggests that (1)
normokalemic patients with advanced renal failure
frequently have high levels of plasma aldosterone,
particularly when the clearance of creatinine is be-
low 15 mI/mm, (2) these levels can be further in-
creased by maneuvers that normally stimulate al-
dosterone secretion, including sodium restriction
and upright posture, and (3) the hormone exerts a
significant antinatriuretic and kaliuretic influence
in patients with advanced renal failure, even during
a normal sodium intake, and thus appears to be an
important factor in volume and potassium homeo-
stasis over a wide range of renal function, including
far-advanced chronic renal failure.
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